Anti-gp210-positive primary biliary cholangitis: The dilemma of clinical treatment and emerging mechanisms.
暂无分享,去创建一个
Bangmao Wang | Lu Zhou | Zhen Yang | Xiaoyi Wang | Long Li | Ying Ran
[1] Rui Zhong,et al. The prognostic value of antibodies to gp210 among patients with primary biliary cholangitis in Northeast China. , 2021, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[2] P. Trivedi,et al. Antibodies to gp210 and understanding risk in patients with primary biliary cholangitis , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[3] A. Granito,et al. Surrogate Markers for Antimitochondrial Antibody-Negative Primary Biliary Cholangitis. , 2020, The American journal of gastroenterology.
[4] gui-qiang Wang,et al. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators. , 2020, Clinics and research in hepatology and gastroenterology.
[5] Liangdan Sun,et al. Genome‐wide Association Studies of Specific Antinuclear Autoantibody Subphenotypes in Primary Biliary Cholangitis , 2019, Hepatology.
[6] J. Anaya,et al. Molecular mimicry and autoimmunity. , 2018, Journal of autoimmunity.
[7] J. Boyer,et al. Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[8] J. Fang,et al. The risk predictive values of UK‐PBC and GLOBE scoring system in Chinese patients with primary biliary cholangitis: the additional effect of anti‐gp210 , 2017, Alimentary pharmacology & therapeutics.
[9] Jing-Yuan Fang,et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy , 2017, Gut.
[10] T. Saibara,et al. Autoantibody status and histological variables influence biochemical response to treatment and long‐term outcomes in Japanese patients with primary biliary cirrhosis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.
[11] A. Granito,et al. Fatigue and pruritus at onset identify a more aggressive subset of primary biliary cirrhosis , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[12] Minoru Nakamura. Clinical Significance of Autoantibodies in Primary Biliary Cirrhosis , 2014, Seminars in Liver Disease.
[13] I. Mackay,et al. Epitope‐specific anti‐nuclear antibodies are expressed in a mouse model of primary biliary cirrhosis and are cytokine‐dependent , 2012, Clinical and experimental immunology.
[14] C. Selmi,et al. Overcoming a “Probable” Diagnosis in Antimitochondrial Antibody Negative Primary Biliary Cirrhosis: Study of 100 Sera and Review of the Literature , 2012, Clinical Reviews in Allergy & Immunology.
[15] A. Granito,et al. Antinuclear antibodies as ancillary markers in primary biliary cirrhosis , 2012, Expert review of molecular diagnostics.
[16] H. Nagamune,et al. The role of CD18 in the production and release of neutrophils from the bone marrow , 2010, Laboratory Investigation.
[17] A. Granito,et al. Multiple nuclear dots and rim-like/membranous IgG isotypes in primary biliary cirrhosis , 2009, Autoimmunity.
[18] D. Vergani,et al. Anti‐gp210 antibody mirrors disease severity in primary biliary cirrhosis , 2007, Hepatology.
[19] Masahiro Ito,et al. Anti‐gp210 and anti‐centromere antibodies are different risk factors for the progression of primary biliary cirrhosis , 2007, Hepatology.
[20] R. Chapman,et al. Antinuclear antibodies giving the ‘multiple nuclear dots’ or the ‘rim‐like/membranous’ patterns: diagnostic accuracy for primary biliary cirrhosis , 2006, Alimentary pharmacology & therapeutics.
[21] Masahiro Ito,et al. Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. , 2006, Journal of autoimmunity.
[22] K. Migita,et al. Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. , 2005, Journal of hepatology.
[23] Wolfram Antonin,et al. The integral membrane nucleoporin pom121 functionally links nuclear pore complex assembly and nuclear envelope formation. , 2005, Molecular cell.
[24] S. Matsushita,et al. Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. , 2003, Gastroenterology.
[25] K. Miyachi,et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. , 2003, Journal of autoimmunity.
[26] G. Bianchi,et al. Characterization and Clinical Impact of Antinuclear Antibodies in Primary Biliary Cirrhosis , 2003, American Journal of Gastroenterology.
[27] M. Manns,et al. The antinuclear autoantibodies Sp100 and gp210 persist after orthotopic liver transplantation in patients with primary biliary cirrhosis. , 1998, Journal of hepatology.
[28] H. Asakura,et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis , 1998 .
[29] M. Manns,et al. Persistence of autoantibodies against recombinant mitochondrial and nuclear pore proteins after orthotopic liver transplantation for primary biliary cirrhosis. , 1997, Journal of autoimmunity.
[30] J. Courvalin,et al. Specificity and sensitivity of gp210 autoantibodies detected using an enzyme‐linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis , 1996, Hepatology.
[31] H. Worman,et al. Autoantibodies from patients with primary biliary cirrhosis recognize a restricted region within the cytoplasmic tail of nuclear pore membrane glycoprotein Gp210 , 1993, The Journal of experimental medicine.
[32] G. Blobel,et al. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. , 1990, The Journal of clinical investigation.
[33] U. Greber,et al. A major glycoprotein of the nuclear pore complex is a membrane‐spanning polypeptide with a large lumenal domain and a small cytoplasmic tail. , 1990, The EMBO journal.
[34] G. Blobel,et al. Primary structure analysis of an integral membrane glycoprotein of the nuclear pore , 1989, The Journal of cell biology.
[35] M. Plana,et al. Autoantibodies against nuclear envelope‐associated proteins in primary biliary cirrhosis , 1988, Hepatology.
[36] M. Kaplan,et al. Primary Biliary Cirrhosis , 1987, The New England journal of medicine.
[37] A. Floreani,et al. Nuclear membrane-staining antinuclear antibody in patients with primary biliary cirrhosis , 1985, Journal of Clinical Immunology.
[38] N. Ling,et al. Vesicular stomatitis virus glycoprotein is anchored in the viral membrane by a hydrophobic domain near the COOH terminus. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[39] K. Simons,et al. Location of the spike glycoproteins in the Semliki Forest virus membrane. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[40] M. A. Jabbar,et al. Structural domains and organizational conformation involved in the sorting and transport of influenza virus transmembrane proteins. , 1989, Annual review of microbiology.
[41] Chinese Medical Association , 2022, Nature.
[42] E. Hitchman,et al. Brief Definitive Report Autoantibodies from Patients with Primary Biliary Cirrhosis Preferentially React with the Amino-terminal Domain of Nuclear Pore Complex Glycoprotein Gp210 , 2022 .